Within the agreement, Hungarian company will invest US$100 million for construction of plant on production of vaccines and biological medicaments in Uzbekistan in 2010-2013.

Pharmaceutical plant will produce first party of products in March 2012 and in line with the agreement, the plant will produce anti-flu vaccines. The plant will be flexible and can produce required vaccine as flu virus regularly mutates.

The plant will also produce other products. In particular, it is planned to produce adsorbed whooping-cough-diphtheritic-tetanus vaccine, tuberculosis vaccine, and abdominal-typhoid vaccine by mid 2012.

Uzbekistan included these vaccines into National Immunization Calendar and currently buys them from abroad. By June 2013, the plant plans to start to produce biologically active supplements. It is expected that the plant will export 70% of products to the countries of the CIS, Middle East and European Union.

It is expected that the plant will use local medicinal herbs to produce products.

Within the support of the Government of Uzbekistan, Omninvest Development КFT opened its office in Tashkent - Omninvest Asia. Omninvest Asia is responsible for implementation of the project and it will also help to develop cell and genic therapy in Uzbekistan.

In line with the presidential decree, Omninvest Asia was exempted from all tax and custom payments for five years from the start of production.

Omninvest Asia will also organize the Center for cell and genic therapy in Uzbekistan. It is planned to open it in 2013. The Center will help to introduce new methods of treatment into practice.